CarMax earnings analysis: questions answered and next catalysts

CarMax reported FY2027 Q2 EPS of $1.16, beating the $0.73 consensus by 58.9%, while revenue reached $7.88B versus $7.03B expected and grew 19.5% year over year. Used-vehicle comparable sales rose 13.0%, while SG&A increased roughly 5%, indicating meaningful operating leverage; shares climbed 6.22% to $60.07. The recovery thesis is supported by three consecutive earnings beats, improved CarMax Auto Finance trends and potential buyback resumption, though thin 11.8% gross margins and bearish analyst targets of $43 and $31 remain key risks.

Analysis

The investable change is not the earnings surprise itself but evidence that KMX can trade incremental vehicle margin for unit velocity without losing expense discipline. If sustained, faster inventory turns release working capital and reduce markdown risk, allowing earnings to compound faster than the currently thin retail margin would imply; however, this thesis requires stable gross profit per unit and CAF credit losses, neither of which is established by the release. A move through the prior high would likely pull in momentum buyers ahead of November, but the stock now embeds a meaningful portion of a successful execution narrative.

CVNA is the relevant competitive read-through: KMX's pricing flexibility can force more rational used-car pricing and raise customer-acquisition costs for a digital-first competitor, though CVNA's higher operating leverage means it could still outperform if affordability improves broadly. The more important macro sensitivity is funding cost: lower benchmark rates help loan affordability, but a volatile or widening auto-asset-backed-securities market can offset that benefit at CAF and constrain loan economics. Over the next 1-3 months, revisions and the strategic event matter more than another headline beat; over 6-18 months, KMX must demonstrate that volume gains do not merely pull forward demand or worsen credit selection.

Consensus appears too focused on the sequential beat streak and too little on the quality of financing earnings. Buybacks are only accretive if CAF is not using balance-sheet capacity that will be needed for higher delinquencies, inventory financing, or securitization spreads. The recovery thesis is falsified by used comps falling below mid-single digits, retail GPU declining materially, CAF provision/loan rising, or November guidance implying SG&A growth catches revenue growth.

Key Decisions for Investors

• Tactically long KMX only on a decisive break above $65.28 or a post-event pullback that holds $55-$57; target $72-$75 into December earnings, with a stop below $52. The setup offers roughly 2:1 upside/downside only if November provides measurable unit-growth, margin, and expense targets.
• Prefer a defined-risk KMX November/January call spread rather than outright calls: buy Jan-2027 $65 calls and sell $75 calls after implied volatility is assessed. The strategic update is the catalyst; abandon if management provides narrative targets without CAF credit, GPU, and inventory-turn disclosures.
• Monitor a KMX long / CVNA short pair after KMX confirms a breakout, sized beta-neutral and held through the November event. The spread thesis is KMX gaining share through omnichannel scale and pricing discipline; exit if CVNA reports superior unit growth without deterioration in retail GPU or leverage metrics.
• Do not underwrite buyback-driven EPS upside until management confirms repurchase size, funding source, and CAF securitization spreads. A widening in auto ABS spreads or rising CAF loss provisions is an immediate risk-off signal for KMX despite stronger retail volumes.